1.	Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-067, NCT01169649
2.	A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 91 Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_547, MK-2206-003, NCT00848718
3.	A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_646, MK2206-015, NCT00963547